Kornimate/medical-research-clean huggingface dataset:
the effect of virtual reality application on pain, anxiety, and comfort during curettage/dilatation

Conditions: Bleeding;Post D&C; PAIN, ANXIETY, AND COMFORT

Summary: the problems experienced by women at the stage of deciding to have a miscarriage, during and after miscarriage differ and their anxiety levels vary. it was determined that women experienced fear, thinking that they would sin, guilt, regret and indecision at the stage of deciding to abort. methods are used to relieve the pain and anxiety caused by interventional procedures in patients in direct proportion to the development of technology. virtual reality (vr), one of these methods, is an innovative, up-to-date and unique application, combining reality and imagination with fictional technology.there is no study in the literature on the application of sg during curettage/dilatation procedure. this study was conducted to determine the effect of sg application on pain anxiety and comfort during curettage/dilatation procedure.


Eligibility criteria:
inclusion criteria: * 15-49 years old, * termination ordered, * can speak and understand turkish, exclusion criteria: * - cognitive, effective and without any problem preventing communication, * no psychiatric problems, * diagnosed with epilepsy (due to the risk that sg glasses may trigger epileptic seizures), * women who volunteer to participate in the study will be recruited.
educational programs based on healthy habits to improve quality of life and psychosocial profile in women with neurodegenerative diseases: the advice protocol study (phase 2)

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting

Summary: this phase of the project aims to compare in-person, supervised educational programs (ep) with online self-guided eps in individuals with relapsing-remitting multiple sclerosis. a total of 75 participants will be randomly assigned to one of three groups: a supervised and individualized educational program focused on hiit training, a supervised and individualized educational program focused on strength training, and a non-supervised, self-guided educational program based on resistance band training. additionally, sessions on the mediterranean diet (both supervised and non-supervised) and cognitive-behavioral interventions will be included. a control evaluation will be conducted three months after the intervention to assess the effects of the educational programs, followed by another evaluation three months later to analyze residual effects. women who participated in phase 1 of the study will be invited to take part in this second phase.


Eligibility criteria:
inclusion criteria include: * women and men of reproductive age (18-45 years) with ms will be included, with the upper age limit adjusted to reflect the reproductive phase; * no iron-deficiency anemia; * stable disease phase; * independent walking ability for over 10 meters. women will be recruited first and later matched with men based on age, edss, and lifestyle habits (physical activity, smoking, and alcohol consumption). exclusion criteria will include participants with ms who: * score \ 6 on the edss; * report a relapse within 12 months before the study begins; * have taken corticosteroid treatment within the last 2 months; * have participated in a structured training program in the previous 6 months. once all women with ms are recruited, male participants will be recruited following a 1:1 matching methodology based on age, geographic region, and lifestyle habits.

Keywords: relapsing-remitting ms fatigue cognitive behavioral therapy physical exercise dietary habits women&#39;s health
steroid vs. anti-vascular endothelial growth factor for diabetic macular edema prior to phacoemulsification

Conditions: Diabetic Macular Edema; Cataract

Summary: the primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

in patients with pre-existing diabetic macular edema, anti-vascular endothelial growth factor therapy (bevacizumab, ranibizumab, or aflibercept) will be compared to ozurdex therapy administered 1 week prior to phacoemulsification cataract extraction. spectral domain optical coherence tomography and visual acuity will be acquired at 1 week, 1 month, 2 months, and 3 months following cataract surgery.

Eligibility criteria:
inclusion criteria: * age \> 18 years of age * gender- all * race- all * diagnosis of diabetes (type 1 or 2) with a concomitant diagnosis of diabetic macular edema as demonstrated on spectral domain optical coherence tomography (heidelberg spectralis) * \>250 microns central foveal thickness * able and willing to provide informed consent exclusion criteria: * significant renal disease * a condition that in the opinion of the investigator would preclude participation * participation in another investigational trial within 30 days of randomization * application of focal macular laser within 120 days of enrollment * administration of iluvien implant within 3 years of enrollment * administration of intravitreal triamcinolone within 3 months of enrollment * administration of any anti-vascular endothelial growth factor agent within 30 days of enrollment * known hypersensitivity to any of the investigational products * blood pressure \>180/110 * women who are pregnant, lactating, or intend to become pregnant within 1 year of randomization * vulnerable populations- including but not limited to wards of the state, cognitively impaired individuals, prisoners, institutionalized individuals * individual is planning on moving within 6 months of study enrollment * macular edema secondary to cause other than diabetic macular edema * ocular condition that, in the opinion of the investigators, may affect course of macular edema during course of study (vein occlusion, uveitis, etc.) * evidence of ocular infections * evidence of uncontrolled glaucoma * known hypersensitivity to any components of bevacizumab, ranibizumab, aflibercept, or ozurdex
genomic medicine for ill neonates and infants (the gemini study)

Conditions: Pediatric: Genetic Syndrome

Summary: the genomic medicine for ill neonates and infants (the gemini study) is a research study aimed at comparing the clinical and economic utility of performing rapid whole genomic sequencing versus a targeted genomic sequencing panel on neonates and infants suspected of having a genetic disorder. this study is funded by the national institutes of health. this multicenter, prospective clinical trial will enroll 400 subjects at the floating hospital for children at tufts medical center (boston, ma), cincinnati children's hospital medical center (cincinnati, oh), mount sinai kravis children's hospital (new york, ny), north carolina children's hospital (chapel hill, nc), children's hospital of pittsburgh (pittsburgh, pa), and rady children's hospital (san diego, ca).

this multicenter, prospective clinical trial will examine the diagnostic yield and clinical utility of newborndx, a targeted genomic sequencing panel for use in the neonate, and rapid whole genomic sequencing (rwgs) testing in high-risk infants with signs/symptoms consistent with a possible genetic disorder. infants will undergo newborndx and rwgs (proband) testing. the biological parent(s), when available, will undergo newborndx testing at the same time as the infant. for rwgs,the infant will undergo testing first. if a specific diagnosis that is consistent with the phenotype is not made with rwgs proband analysis alone, the parent(s) will undergo rwgs. the study will also evaluate the cost effectiveness of each test as well as standard of care (soc) testing. a retrospective chart review of infants with suspected genetic disorders will be done to understand 1-year cost and health outcomes that would have been incurred in the absence of the advanced testing. the resulting data from the trial will be used in the economic evaluation comparing newborndx, rwgs, and soc over a 1-year period and used as basis to simulate the lifetime cost-effectiveness of these testing strategies. a web-based clinical reference database to provide references, clinical management guidelines, opportunities for clinical trial participation, and support groups for each condition will be developed with separate interfaces for the parent/guardian(s) and medical provider. the clinical reference database will be qualitatively assessed by a survey of medical providers.

Eligibility criteria:
inclusion criteria: * documented informed consent from the parent/guardian * signs/symptoms consistent with a possible genetic disorder * admitted to a hospital participating in this study at the time of enrollment * less than one year corrected gestational age exclusion criteria: * a known genetic diagnosis (e.g. prenatal testing) * major congenital anomaly associated with a chromosomal anomaly detected on prenatal testing * presence of documented congenital infection * infants considered non-viable due to prematurity (\< 23 0/7 weeks ga)
accommodation measurements after bilateral implantation of an aspheric accommodating lens and monofocal aspheric lenses

Conditions: Cataract

Summary: the objective of this study is to demonstrate the correlation of near vision and changes in higher order aberrations following lens extraction and to characterize the defocus curves of crystalens® ao™ intraocular lens (iol) versus the monofocal aspheric sofport® li61ao iol in adults.


Eligibility criteria:
inclusion criteria: * subjects must have clear intraocular media other than cataract. * subjects must have a clinically documented diagnosis of age-related bilateral cataracts that are considered amenable to treatment with standard phacoemulsification cataract extraction. * subjects must be undergoing primary iol implantation for the correction of aphakia following central continuous curvilinear anterior capsulorrhexis and phacoemulsification cataract extraction. * subjects must require a spherical lens power from 10.00 d to 30.00 d. * subjects must be willing and able to return for all scheduled follow-up examinations for each eye from days 1 through 180 following surgery. * subjects must have ≤ 1.25 d of preoperative corneal astigmatism. exclusion criteria: * subjects with corneal pathology potentially affecting topography. * subjects whose fundus cannot be assessed preoperatively. * subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level worse than 20/30 as verified by oct. * subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome. * subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis. * subjects with uncontrolled glaucoma. * subjects with previous retinal detachment. * subjects with visually significant diabetic retinopathy (proliferative or non-proliferative) which reduces potential acuity to 20/30 or worse. * subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract. * subjects with marked microphthalmos or aniridia. * subjects who have had previous corneal surgery. * subjects with irregular corneal astigmatism. * subjects with amblyopia which reduces potential acuity to worse than 20/30. * subjects with optic atrophy. * subjects with iris neovascularization. * subjects with clinically significant retinal pigment epithelium/macular changes which reduces potential acuity to 20/30 or worse. * subjects with chronic use of systemic steroids or immunosuppressive medications. * subjects lacking intact binocular vision.

Keywords: cataract surgery intraocular lens
comparison study of echocardiography and cardiovascular magnetic resonance imaging in the assessment of mitral and aortic regurgitation

Conditions: Mitral Regurgitation; Aortic Regurgitation

Summary: the primary treatment for patients determined to have severe aortic or mitral regurgitation is surgical repair or replacement their valves. the most commonly used tool to quantify the severity mitral and aortic regurgitation is echocardiography. studies have shown that echocardiography may have significant limitations in quantifying regurgitant volume. mri has recently been shown to easily and reproducibly quantify regurgitation. to better understand how to accurately quantify severity of regurgitation the investigators propose this study with the following aims: 1) compare mri to echocardiography in the evaluation of regurgitant volume in patients with aortic or mitral regurgitation and 2) to assess which technique is better at predicting the response of the left ventricle to valve surgery.

the primary treatment for patients determined to have severe aortic or mitral regurgitation is surgical repair or replacement their valves. the most commonly used tool to quantify the severity mitral and aortic regurgitation is echocardiography. studies have shown that echocardiography may have significant limitations in quantifying regurgitant volume. mri has recently been shown to easily and reproducibly quantify regurgitation. to better understand how to accurately quantify severity of regurgitation the investigators propose this study with the following aims: 1) compare mri to echocardiography in the evaluation of regurgitant volume in patients with aortic or mitral regurgitation and 2) to assess which technique is better at predicting the response of the left ventricle to valve surgery.

Eligibility criteria:
inclusion criteria: * age ≥18 years of age * able to give informed consent * referred for isolated aortic or mitral valve repair or replacement due to valve regurgitation exclusion criteria: * inability to provide consent. * pregnancy * claustrophobia * metallic contraindications to mri (e.g. noncompatible aneurysm clip etc) * known intracardiac shunt * planned concomitant cardiac surgical procedure such as coronary artery bypass, septal myomectomy, or other valve procedure. * more than mild mitral or aortic stenosis. * for patients enrolled with mitral regurgitation: greater than mild aortic regurgitation. * for patients enrolled with aortic regurgitation: greater than mild mitral regurgitation. * hypertrophic cardiomyopathy.
the effect of glucagon-like peptide-1 (glp-1) on pulmonary vascular resistance (pvr) in patients with heart failure

Conditions: Heart Failure

Summary: this study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.


Eligibility criteria:
inclusion criteria: * age over 18 * able to give informed consent * on the waiting list for heart transplant * left ventricular dysfunction awaiting catheterisation exclusion criteria: * nicorandil, glibenclamide, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist or insulin * women of child bearing age and breast feeding women * cardiac pacemaker or other implanted metallic device * unable to give informed consent
sensitivity of self-collected skin sampling for scabies: a pilot study

Conditions: Scabies

Summary: in this cross-sectional diagnostic study, healthy adults aged 18 and older with suspected, clinical, or confirmed scabies will be recruited. the objective is to determine if the sensitivity of self-collected skin samples for scabies diagnosis is non-inferior to professional sampling, and compare the sensitivity and specificity of the polymerase chain reaction assay (pcr) versus microscopy.

scabies infestations have significantly increased globally in the last 10-20 years, including a threefold rise in the netherlands over the past decade. diagnosing scabies is challenging due to varied symptoms and low sensitivity of current microscopic methods. new diagnostic techniques like pcr, which offer higher sensitivity, are being investigated. the feasibility of self-collected skin samples is being explored to reduce the burden on healthcare services and address issues like autonomy, stigma, and privacy. in this cross-sectional diagnostic study, healthy adults aged 18 and older with suspected, clinical, or confirmed scabies will be included. primary endpoint is the sensitivity of self-collected versus professional skin samples for diagnosing scabies. secondary endpoints include sensitivity of skin scrapings and swabs, and the sensitivity and specificity of pcr versus microscopy. participants will self-collect skin samples during a standard care visit. the process may be slightly sensitive but not painful. there are no direct benefits beyond standard care.

Eligibility criteria:
inclusion criteria: * 18 years or older * have either suspected scabies, clinical scabies or confirmed scabies (see table 1) * providing informed consent (ic) exclusion criteria: * individuals not speaking or understanding the dutch or english language. * individuals who have been diagnosed with scabies in the last six weeks and had started treatment. * individuals who have used ivermectin for other diagnoses than scabies in the last six weeks. * individuals younger than 18 years. * individuals with immunosuppressive conditions (see appendix a). * any other condition, finding or situation which, in the opinion of the investigator, may significantly increase the risk to the individual because of participation in the study, affect the ability of the individual to participate in the study or impair interpretation of the study data.
rosuvastatin in preventing myonecrosis in elective percutaneous coronary interventions (pcis)

Conditions: Periprocedural Myocardial Necrosis

Summary: an increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after otherwise successful percutaneous coronary interventions (pcis)(1) apart from side-branch occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after pci might be distal embolization of atherogenic materials from plaque disruption,(2 )causing obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )recent studies have suggested that pretreatment with atorvastatin may be associated with a reduction in infarct size after elective pci. (5-7 ).actually the standard pretreatment in patients undergoing elective coronary-pci and already treated with aspirin is copidogrel loading dose administration before procedure.(8,9 ) the investigators hypothesized that a high (40mg) loading dose of rosuvastatin administered within 24h before the procedure may be effective in reducing the rate of periprocedural mi.therefore, the investigators will conduct a single center,prospective randomized study to assess whether a single,high (40mg) loading (within24h)dose of rosuvastatin is effective in preventing elevation of biomarkers of mi after elective coronary stent implantation.


Eligibility criteria:
inclusion criteria: * patients with stable angina exclusion criteria: * baseline myocardial enzyme rise

Keywords: percutaneous angioplasty myocardial infarction
the efficacy and safety of beta-blockers drugs in adults with spinal hemangioma

Conditions: Spinal Tumor; Spinal Hemangioma; Beta Blocker Toxicity

Summary: spinal hemangioma is one of the most common benign vertebral tumours. being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. this study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.


Eligibility criteria:
inclusion criteria: * vertebral hemangioma exclusion criteria: * symptomatic bradycardia * av block * decompensated heart failure * asthma

Keywords: β-blockers vertebral hemangioma efficacy
effects of thc on alcohol consumption and neural correlates of reward

Conditions: Cannabis Use Disorder

Summary: alcohol and cannabis are often used together such that their effects overlap, but little is known about the neural mechanisms that underlie simultaneous use. high doses of thc have not been well-studied in the laboratory, and it is unclear how high doses of thc may impact alcohol consumption patterns. the proposed study will explore the effects of oral thc (20mg dronabinol) vs. placebo on neural reward, alcohol self-administration and naturalistic co-use patterns.

participants will undergo a screening assessment, baseline session and two laboratory visits. the laboratory visits will involve an mri scan and the opportunity to consume alcohol in our bar lab. prior to the mri, participants will consume, a placebo (0mg) or high (20mg) dose of oral thc (dronabinol). visits will be separated by 7 to 14 days. dronabinol is an fda-approved product that will be dispensed by our on-campus pharmacy

Eligibility criteria:
inclusion criteria: * drink alcohol * use cannabis * contact site for additional details exclusion criteria: * mri contraindications (implanted metal, weight \> 315 lb, etc.). * contact site for additional details
anti-factor xa based venous thromboembolism prophylaxis

Conditions: Dose Adjustment of Enoxaparin in ICU Patients

Summary: introduction: venous thromboembolism (vte) in the intensive care unit (icu) is associated with significant morbidity and mortality therefore prevention is imperative to reduce its burden. vte prophylaxis in icu patients is primarily pharmacological using low molecular weight heparin. this study aims to determine the proportion of icu patients receiving vte prophylaxis that achieves appropriate anti-factor xa activity (afxa) prophylactic levels and to characterize this patient population methods: seventy-five patients admitted to the general icu were included. peak and trough afxa levels were measured at 4 and 23 hours respectively after receiving the second consecutive daily enoxaparin 40 mg sc injection. patients in whom peak afxa levels were found to be sub-prophylactic, peak and trough levels were repeated as above


Eligibility criteria:
inclusion criteria: inclusion criteria were age over 18 years and a predicted icu stay of more than 72 h. - exclusion criteria: exclusion criteria were any contraindication for heparin-based thromboembolic prophylaxis, patients with an indication for therapeutic anticoagulation , administration of unfractioned-heparin or low-molecular-weight-heparin prior to study entry, active hemorrhage, or creatinine clearance \< 30 ml/min. -
pregabalin in the treatment of pain due to diabetic peripheral neuropathy

Conditions: Diabetic Neuropathy, Painful

Summary: the purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.


Eligibility criteria:
inclusion criteria: * adults with type 1 or 2 diabetes * patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months exclusion criteria: * patients must not be in poor or unstable health.